ZykadiaCyramzaFruzaqlaFruquintinibImfinzidurvalumabramucirumabBrigatinibceritinib
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
8articles mentioning drugs
32drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Abemaciclib ×
Abemaciclib
This drug is selected. Its supporting articles are shown below.
Articles mentioning Abemaciclib
8 articles · page 1 of 1abemaciclibribociclibpalbociclibfulvestrantanastrozoleletrozolebreast cancerRegional University Hospital of Málagaendocrine therapy
…have doubled progression-free survival. Approved agents include abemaciclib, palbociclib, and ribociclib. In the MONARCH 2 trial, abemacicl…
abemaciclibadjuvant therapyALBC
…vance Despite the limited sample size, the results suggest that abemaciclib’s effectiveness seems consistent with MONARCH-3 results:Median …
AbemaciclibAbemaciclib-inducedDMSOCDK4/6istriple-negative breast cancerBCTNBC
…t cancer cell lines—CAMA1 (HR+) and MDAMB231 (TNBC)—with either Abemaciclib or DMSO, and analyzed the MHC I-bound antigen repertoire using …
97.4%
Abemaciclib
…Background and Importance Abemaciclib is a CDK4/6 inhibitor (CDKi) indicated for treatment of HER2 ne…
palbociclibribociclibabemaciclibCurcuma longacurcuminbreast cancerLee et al
…ent kinase 4/6 inhibitors (CDK4/6i)—abemaciclib, ribociclib and palbociclib—have transformed the treatment of hormone receptor-positive, HE…
abemaciclibribociclibpalbociclibWithania somniferaAshwagandhahormone receptor-positive, HER2-negative metastatic breast cancer
…4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib and abemaciclib, has transformed the prognosis of hormone receptor-positive, HE…
enzalutamideapalutamidepazopanibabirateroneolaparibsunitinibcapecitabineimatinibosimertinibabemaciclib+8 more
… 5% had ovarian, renal or lung cancer. The involved drugs were: enzalutamide(25), apalutamide(14), abiraterone (9), abemaciclib(6), capecita…